Titlebook: Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology; Scientific and Clini M. R. Nowrousian Book 20021st edition Springer-Verlag/W

賞心悅目

Relationship between anemia and tumor hypoxia, satisfy the oxygen demand (Vaupel et al. 1989). The complex pathophysiological mechanisms have recently been reviewed (H?ckel and Vaupel 2001). Hypoxia seems to represent a general pathophysiological phenomenon in solid cancers and is associated with more rapid malignant progression and poor progno

expire

Tumor hypoxia and therapeutic resistance,e to the lack of methods suitable for the routine measurement of intratumoral oxygen tensions in patients. In the late 1980s, a novel and clinically applicable standardized procedure was established enabling the determination of tumor oxygenation in accessible primary tumors, local recurrences, and

生命

Albinism

Relationship between anemia, fatigue, and quality of life in cancer patients,anced stages of cancer (Groopman and Itri 2000; Khayat 2000). The clinical symptoms of anemia, such as fatigue, dyspnoea, vertigo, loss of appetite, and inability to concentrate impair the patients physical functioning and subjective sense of well-being (Groopman and Itri 2000). By relieving these s

GOUGE

Red blood cell transfusion, risks and limitations, tissues induced by surgical related anemia, but it is now perceived as a procedure to be avoided. The safety of blood supply has been in question since the first cases of transfusion transmitted AIDS in the early 1980. In response to this crisis blood collection centres implemented a successful mul

Metamorphosis

Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin (rhEPO),enation is the primary determinant of the expression of the EPO gene in the kidney. Other production sites contribute little to circulating EPO in humans after birth, albeit the liver is the main site of EPO mRNA expression in fetuses. EPO inhibits the programmed cell death (apoptosis) of the erythr

DIS

Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin manifested at the time of diagnosis. In patients with MM, hemoglobin values <10.0g/dL were found in 49% and severe anemia (hemoglobin <7.5 g/dL) in 19% of the patients already at the time of diagnosis (MRC working party 1980). Patients with NHL have been reported to have an anemia rate of approxima

Lamina

小卷發(fā)

enlist